Table 2.

Clinical symptoms after rifaximin treatment of the IBS patients.

Clinical symptoms	IBSN (n = 76)	IBSNt (n = 15)	IBSP (n = 51)	IBSPt (n = 24)	P1	P2
IBS-SSS
Abdominal pain	59.11 ± 5.29	22.86 ± 6.71	62.5 ± 7.02	20.91 ± 5.79	0.001	0
Pain frequency	40.20 ± 4.64	28.57 ± 8.84	33.08 ± 4.86	26.36 ± 7.41	0.326	0.505
Bloating	25.82 ± 2.86	15.71 ± 7.82	24.50 ± 3.49	15.91 ± 5.17	0.257	0.235
Dissatisfaction with bowel movement	64.44 ± 10.56	39.44 ± 9.73	70.00 ± 5.43	41.92 ± 6.19	0.101	0.002
Disturbance to life	60.13 ± 2.73	49.29 ± 8.76	59.15 ± 3.22	46.36 ± 4.91	0.213	0.036
Bristol	5.30 ± 0.13	4.79 ± 0.39	5.48 ± 0.12	4.20 ± 0.13	0.111	0
GSRS
Abdominal pain	5.27 ± 0.22	4.29 ± 0.78	6.06 ± 0.33	4.50 ± 0.64	0.185	0.050
Bloating	7.81 ± 0.46	7.71 ± 1.13	8.54 ± 0.55	6.70 ± 0.91	0.949	0.156
Diarrhea	13.66 ± 0.75	11.71 ± 1.85	14.88 ± 0.87	9.50 ± 0.62	0.418	0
Constipation	2.72 ± 0.21	2.14 ± 0.14	3.46 ± 0.32	3.20 ± 0.47	0.387	0.726
Satiety	4.06 ± 0.32	3.86 ± 0.46	6.21 ± 0.51	4.70 ± 0.63	0.843	0.077

Data were described as mean ± standard deviation. P1: P value of IBSN vs. IBSNt; P2: P value of IBSP vs. IBSPt. GSRS: Gastrointestinal Symptom Rating Scale; IBS: Irritable bowel syndrome; IBSNt: Patients in IBSN after rifaximin treatment; IBSPt: Patients in IBSP after rifaximin treatment; IBS-SSS: IBS Symptom Severity Scores; IBSP: Breath test positive IBS patients; IBSN: Breath test negative IBS patients.